<\/p>\n
We are very pleased to announce that, as of July 30<\/strong>, Quebec has become the first Canadian province<\/strong> to officially list ANDEMBRY\u00ae<\/strong> on its public drug formulary, providing eligible patients with access to this new preventive treatment for hereditary angioedema (HAE)<\/strong>.<\/p>\n ANDEMBRY\u00ae<\/strong> is now reimbursed according to the reimbursement criteria recommended by INESSS<\/strong>:<\/p>\n This first provincial listing represents a major milestone toward broader access to ANDEMBRY\u00ae<\/strong> across Canada and reflects CSL’s commitment<\/strong> to expanding treatment options for people living with hereditary angioedema.<\/p>\n We would like to sincerely thank everyone who contributed to this important achievement. This milestone is the result of a collective effort and outstanding collaboration among all those involved.<\/p>\n CSL remains fully committed to ensuring timely access to ANDEMBRY\u00ae for all eligible patients across Canada.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":" We are very pleased to announce that, as of July 30, Quebec has become the first Canadian province to officially list ANDEMBRY\u00ae on its public drug formulary, providing eligible patients with access to this new preventive treatment for hereditary angioedema (HAE). ANDEMBRY\u00ae is now reimbursed according to the reimbursement criteria recommended by INESSS: For… Read More<\/a>En savoir plus<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-4084","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\n\n